Multiple Sclerosis | |
|---|---|
| Study Name | Principal Investigator |
| MN43964 – A Multicenter, Single-Arm, Open-Label, Extension, Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab of in Patients with Multiple Sclerosis. Read more. |
Mary Ann Picone, MD |
| GN41791 – A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sclerosis (FENtrepid). Read more. |
Asya Wallach, MD |
| 257MS201 – A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis (FUSION). Read more. |
Mary Ann Picone, MD |
| EFC17504 – A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis (FREVIVA). Read more. |
Mary Ann Picone, MD |
| ZB012-02-002 – A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab, in Patients with Relapsing Multiple Sclerosis. Read more. |
Mary Ann Picone, MD |
| TG1101-RMS406 – Real world experience with BRIUMVI® (ublituximAB-xiiy) treated patients: A longitudinal registry study (ENABLE). Read more. |
Mary Ann Picone, MD |
| COMB157Q12301 – An open-label, randomized, parallel-group, non-inferiority study to investigate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new maintenance dosing regimen of ofatumumab, followed by extended treatment in participants with relapsing multiple sclerosis. Read more. |
Mary Ann Picone, MD |
